Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan.

[1]  S. Miyano,et al.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.

[2]  J. Cortes,et al.  Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  H. Nakasone,et al.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups , 2016, Haematologica.

[4]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[5]  S. Ogawa,et al.  High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation , 2016, Haematologica.

[6]  M. Kurokawa,et al.  Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study. , 2016, Leukemia research.

[7]  J. Esteve,et al.  Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT , 2016, Haematologica.

[8]  K. Rezvani,et al.  Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  A. Ganser,et al.  Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation , 2015, British journal of haematology.

[10]  Y. Miyazaki,et al.  Allogeneic haematopoietic cell transplantation with reduced‐intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study , 2015, British journal of haematology.

[11]  M. Perales,et al.  Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Kanda.  Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation , 2015, International Journal of Hematology.

[13]  Y. Atsuta.  Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) , 2015, International Journal of Hematology.

[14]  P. Cauchy,et al.  A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia , 2014, Leukemia.

[15]  J. Bourhis,et al.  Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire , 2013, European journal of haematology.

[16]  Y. Ohashi,et al.  In vivo T‐cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA‐mismatched haploidentical transplantation , 2013, American journal of hematology.

[17]  J. Kanda,et al.  Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction , 2013, Leukemia.

[18]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[19]  T. Lamparelli,et al.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  S. Yun,et al.  Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. , 2011, Blood.

[21]  F. Atem,et al.  Activity of azacitidine in chronic myelomonocytic leukemia , 2011, Cancer.

[22]  H. Deeg,et al.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  G. Mufti,et al.  Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience , 2010, Bone Marrow Transplantation.

[24]  L. Luznik,et al.  High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation , 2010, Immunologic research.

[25]  J. Rossen,et al.  Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes , 2010, Biology of Blood and Marrow Transplantation.

[26]  N. Kröger,et al.  Outcome of allo-SCT for chronic myelomonocytic leukemia , 2009, Bone Marrow Transplantation.

[27]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  K. Kawa,et al.  Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. , 2009, Blood.

[29]  H. Azuma,et al.  Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis , 2008, Bone Marrow Transplantation.

[30]  Hisashi Yamamoto,et al.  Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  M. Lübbert,et al.  Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). , 2006, Leukemia research.

[32]  M. Beran.  Chronic myelomonocytic leukemia. , 2008, Cancer treatment and research.

[33]  K. Kawa,et al.  Unification of Hematopoietic Stem Cell Transplantation Registries in Japan and Establishment of the TRUMP System , 2007, International journal of hematology.

[34]  E. Estey,et al.  Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). , 2007, Blood.

[35]  K. Sullivan,et al.  Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Ansell,et al.  Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia , 2006, Bone Marrow Transplantation.

[37]  S. Asano,et al.  Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. , 2004, Blood.

[38]  J. Wagner,et al.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. , 2004, The New England journal of medicine.

[39]  M. Labopin,et al.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. , 2004, The New England journal of medicine.

[40]  U. Germing,et al.  Risk Assessment in Chronic Myelomonocytic Leukemia (CMML) , 2004, Leukemia & lymphoma.

[41]  S. Karandish,et al.  Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia , 2004, Bone Marrow Transplantation.

[42]  H. Deeg,et al.  Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. , 2003, Blood.

[43]  N. Kröger,et al.  Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 2002, British journal of haematology.

[44]  Terry L. Smith,et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.

[45]  M. Beran.  Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. , 2000, International journal of hematology.

[46]  E. Estey,et al.  Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[48]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[49]  A. List,et al.  Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. , 1998, Leukemia research.

[50]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.